Oxaliplatin desensitization for gastrointestinal cancer patients with hypersensitivity reactions: real-world experience from Vietnam
5 affiliations
- 1Pharmacy Department, Vinmec Times City International Hospital , ,
- 2Hanoi University of Pharmacy , ,
- 3College of Health Sciences, VinUniversity , ,
- 4Vinmec-VinUni Institute of Immunology, College of Health Sciences, VinUniversity , ,
- 5Allergy and Immunology Department, Vinmec Times City International Hospital , ,
Abstract
Introduction: Oxaliplatin-induced hypersensitivity reactions (HSRs) can interrupt clinically indicated treatment for gastrointestinal malignancies. We evaluated the early implementation of a multidisciplinary oxaliplatin desensitization pathway at Vinmec Times City International Hospital.
Methods: We conducted a retrospective case series of patients who underwent oxaliplatin desensitization between 2022 and 2025 following an index HSR. Clinical characteristics, skin testing results, desensitization procedures, breakthrough reactions (BTRs), and subsequent oxaliplatin treatment completion were reviewed.
Results: Ten patients underwent desensitization after index HSRs occurring at a median of six oxaliplatin cycles (range, 2–11); six index reactions were Brown grade 2. Skin prick testing was negative in all patients, whereas intradermal testing was positive in six, negative in three, and equivocal in one. Three patients initially underwent a three-bag desensitization procedure and seven a four-bag procedure. Eight BTRs occurred in six patients, none requiring epinephrine. Seven patients completed all additional oxaliplatin cycles planned by their oncology team, receiving a median of four additional cycles. Three patients discontinued oxaliplatin after BTRs: two because of recurrent reactions despite procedure modification and one because the patient declined further treatment after a single BTR in the metastatic setting.
Discussion: Multidisciplinary oxaliplatin desensitization enabled most patients in this early case series to continue and complete planned oxaliplatin treatment, although BTRs were common. Given the small, retrospective cohort, these findings are descriptive and require further study to establish comparative safety or efficacy, superiority of a specific desensitization procedure, or predictors of treatment completion.
Related
- Delayed hypersensitivity reactions caused by iodixanol: An assessment of cross-reactivity in 22 patients
- Guidelines: Diagnosis and management of perioperative immediate hypersensitivity reactions 2025
- Hypersensitivity and Allergic Reactions to PMMA-Based Acrylic Dental Materials in Patients and Dental Personnel: A Narrative Review
- Metal Hypersensitivity Reactions Following Spinal Implants: A Systematic Review.
- Guidelines on the diagnosis and management of perioperative immediate hypersensitivity reactions 2025
BibTeX
@article{nguyen2026oxaliplatin,
title = {{Oxaliplatin desensitization for gastrointestinal cancer patients with hypersensitivity reactions: real-world experience from Vietnam}},
author = {Le Trang Nguyen and Van Thang Nguyen and Hong Thach Nong and Nguyen Thanh Dat Doan and Hoang Tuan La and Thi Mai Vu and Thanh Thien Le and Thanh Dung Quach and Quynh Lan Phan and Van Dinh Nguyen and Ngoc May Le},
journal = {Frontiers in oncology},
year = {2026},
month = sep,
doi = {10.3389/fonc.2026.1876656},
url = {https://europepmc.org/article/PMC/PMC13661475},
note = {CC BY},
}
RIS
TY - JOUR
TI - Oxaliplatin desensitization for gastrointestinal cancer patients with hypersensitivity reactions: real-world experience from Vietnam
AU - Le Trang Nguyen
AU - Van Thang Nguyen
AU - Hong Thach Nong
AU - Nguyen Thanh Dat Doan
AU - Hoang Tuan La
AU - Thi Mai Vu
AU - Thanh Thien Le
AU - Thanh Dung Quach
AU - Quynh Lan Phan
AU - Van Dinh Nguyen
AU - Ngoc May Le
PY - 2026
DA - 2026/09/30
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1876656
UR - https://europepmc.org/article/PMC/PMC13661475
AB - Introduction: Oxaliplatin-induced hypersensitivity reactions (HSRs) can interrupt clinically indicated treatment for gastrointestinal malignancies. We evaluated the early implementation of a multidisciplinary oxaliplatin desensitization pathway at Vinmec Times City International Hospital. Methods: We conducted a retrospective case series of patients who underwent oxaliplatin desensitization between 2022 and 2025 following an index HSR. Clinical characteristics, skin testing results, desensitization procedures, breakthrough reactions (BTRs), and subsequent oxaliplatin treatment completion were reviewed. Results: Ten patients underwent desensitization after index HSRs occurring at a median of six oxaliplatin cycles (range, 2–11); six index reactions were Brown grade 2. Skin prick testing was negative in all patients, whereas intradermal testing was positive in six, negative in three, and equivocal in one. Three patients initially underwent a three-bag desensitization procedure and seven a four-bag procedure. Eight BTRs occurred in six patients, none requiring epinephrine. Seven patients completed all additional oxaliplatin cycles planned by their oncology team, receiving a median of four additional cycles. Three patients discontinued oxaliplatin after BTRs: two because of recurrent reactions despite procedure modification and one because the patient declined further treatment after a single BTR in the metastatic setting. Discussion: Multidisciplinary oxaliplatin desensitization enabled most patients in this early case series to continue and complete planned oxaliplatin treatment, although BTRs were common. Given the small, retrospective cohort, these findings are descriptive and require further study to establish comparative safety or efficacy, superiority of a specific desensitization procedure, or predictors of treatment completion.
SN - 2234-943X
ER -